Disparities in phase 1 cancer clinical trial enrollment-Reference-Cited by-同舟云学术

Disparities in phase 1 cancer clinical trial enrollment

Published:2021-08-11 Issue:23 Volume:127 Page:4464-4469
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Perni Subha¹²^ORCID,Moy Beverly³,Nipp Ryan D.³

Affiliation:

1. Harvard Radiation Oncology Program Massachusetts General Hospital and Brigham and Women's Hospital/Dana‐Farber Cancer Institute Boston Massachusetts

2. Department of Radiation Oncology Massachusetts General Hospital Cancer Center Boston Massachusetts

3. Department of Medicine Division of Hematology and Oncology Massachusetts General Hospital and Harvard Medical School Boston Massachusetts

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33853

Reference23 articles.

1. American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment

2. Phase I trials as valid therapeutic options for patients with cancer

3. Phase I trials in oncology: a new era has started

4. Building a phase 1 cancer research program: lessons learned and progress made;Matrana MR;Ochsner J,2017

5. Participation in Cancer Clinical Trials

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enrollment of underserved racial and ethnic populations in pediatric asthma clinical trials;Journal of Allergy and Clinical Immunology: Global;2024-11

2. Decentralized Clinical Trials in Early Drug Development—A Framework Proposal;Journal of Immunotherapy and Precision Oncology;2024-08-01

3. Outcomes Among Racial and Ethnic Minority Patients With Advanced Cancers in Phase 1 Trials;JAMA Network Open;2024-07-11

4. Participants’ perceptions support the coexistence of benefits and burdens of cancer clinical trial participation;Journal of Psychosocial Oncology;2024-06-22

5. Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program;Contemporary Clinical Trials Communications;2024-06